Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Regulus (RGLS – Research Report) on November 7 and set a price target ...